Randomized controlled clinical trial to evaluate the efficacy of Eladi churna in the management of urdhwag amlapitta with special reference to GERD
Keywords:Urdhwag amlapitta, GERD, Eladi churna, Ama, Pitta
Amlapitta is one of the most common diseases seen in society. The word Amlapitta is made up of Amla and Pitta. Aacharya Kashyapa was the first person who described Amlapitta as a separate disease. Madhav Nidan, Bhavprakash, and Yogratnakara have also described it very well.The disease in which the sour quality of Pitta dosha aggravates and changes to extreme acidic sourness is called Amlapitta. Amlapitta is Annavaha Strotas Vyadhi (gastrointestinal disease), which is caused due to Agnimandya and vitiations of Pachaka Pitta. Urdhwag Amlapitta can be correlated with GERD. Gastroesophageal reflux disease (GERD) is one of the most common gastrointestinal diseases. It is defined on the basis of both esophageal and extra-esophageal symptoms and/or lesions resulting from the reflux of gastric contents into the esophagus. The sign and symptoms of Urdhwag Amlapitta (GERD) are Avipak (Indigestion), Klama (Tiredness), Utklesha (Nausea), Tikta amla udgar (Sour and bitter Belching), Gaurvata (Heaviness), Hruth Kantha Daha (Heart and Throat Burning), and Aruchi (Anorexia).In the present era, consumption of fast food, junk food, anxiety, and depression are the main causes of Amlapitta.In this clinical study, Eladi churna was used, which is described by Yogratnakar in Amlapitta chikitsa .A total of 70 patients were taken, which were divided into two groups of 35 patients for each group. Group A-Eladi Churna ( Trial)and Group B- Amlapittapinashak yog as a control drug mentioned in Bhaishajyaratnawali.
How to Cite
Copyright (c) 2022 International Journal of Ayurvedic Medicine
This work is licensed under a Creative Commons Attribution 4.0 International License.
The author hereby transfers, assigns, or conveys all copyright ownership to the International Journal of Ayurvedic Medicine (IJAM). By this transfer, the article becomes the property of the IJAM and may not be published elsewhere without written permission from the IJAM.
This transfer of copyright also implies transfer of rights for printed, electronic, microfilm, and facsimile publication. No royalty or other monetary compensation will be received for transferring the copyright of the article to the IJAM.
The IJAM, in turn, grants each author the right to republish the article in any book for which he or she is the author or editor, without paying royalties to the IJAM, subject to the express conditions that (a) the author notify IJAM in advance in writing of this republication and (b) a credit line attributes the original publication to IJAM.